Ken Weke

Science-related stuff most of the time | Mass spectrometry | Proteomics | Immunopeptidomics

[Ken Weke @ken_weke]

We successfully detected and quantified proteins involved in glioma pathology and related to immune response. Paper out now :). https://t.co/Py8M2opiDe

[Samuel Hume @DrSamuelBHume]

The new ideas for cancer-targeting engineered T cells are always so interesting

This one hinges on the fact that cancer cells and T cells both use the same mechanism to stop themselves getting cleared by macrophages: the CD47 receptor

So if you block CD47 (with CD47 antibodies), tumour cells are killed by macrophages, but so are T cells

This group tried to solve this by engineering T cells with a variant CD47, which still sends the don't-eat-me signal to macrophages, but is resistant to CD47 antibodies

This means that you can treat with CD47 antibodies, clear cancer cells, and spare the engineered T cells

This is what that this looks like - B6H12 (the CD47 antibody) depletes wildtype, but not engineered (47E NY-ESO-1) T cells:
And in a mouse model of melanoma, CD47 antibodies reduce tumour growth, as do the engineered T cells - but combining them completely shrank tumours for the course of the experiment:
Yamada-Hunter et al. in Nature: https://t.co/gyU8svZFEq

[Ken Weke @ken_weke]

@ben_opuko @ic2_vs Thank you, bro :)

[Ken Weke @ken_weke]

Many thanks to everyone who supported me on this incredible journey!

[CancerVaccines @ic2_vs]

What a day! @ken_weke successfully defended his PhD thesis "Expanding the proteome: Advancing proteomics methodologies to uncover new insights into cancers". The research was done at ICCVS under supervision of prof and co-supervision by dr Sachin Kote.
Congratulations!🎉 🎉🎉

[CancerVaccines @ic2_vs]

What a day! @ken_weke successfully defended his PhD thesis "Expanding the proteome: Advancing proteomics methodologies to uncover new insights into cancers". The research was done at ICCVS under supervision of prof and co-supervision by dr Sachin Kote.
Congratulations!🎉 🎉🎉

[BioMassSpec @realBioMassSpec]

MARS: A Multipurpose Software for Untargeted LC–MS-Based Metabolomics and Exposomics #AC https://t.co/lcSdhg97d7

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC position article and guidelines: Corticosteroid-resistant immune-related adverse events: a systematic review https://t.co/kCXMkFCF0W @LImmunotherapy @AlfredZippelius @cappelliMD @DrJNaidoo

[BioMassSpec @realBioMassSpec]

A Guide to MALDI Imaging Mass Spectrometry for Tissues #JProteomeRes https://t.co/8sM3BEodq2

[Eric Ohuma @ohumaeric]

Our article in @TheLancet’s 200th anniversary issue! An estimated 13.4 million were born preterm in 2020. No decline in preterm rates since 2010! More investment needed. Data gaps exist esp in SSA and we need better data. Read here: https://t.co/ucsGp8C29G
@joylawn @MARCH_LSHTM

[Lappalainen Lab @tuuliel_lab]

Interested in doing a PhD with me in Sweden? Experimental+computational genomics skills or interests? We have an open position! Great environment at KTH on @SciLifeLab campus, staff benefits, well-funded project, close interactions with our New York team. Link in the replies 👇

[Noelle @Noelle_Orata]

Beautifully United to Help End Breast Cancer @FarajaTrust #TimeToEndBreastCancer #BCCKenya

[Ken Weke @ken_weke]

@WorldRemit why are you not replying to DMs, e-mails, and not picking up calls?

[Vadim Demichev @DemichevLab]

We have added DIA-NN 1.8.2 beta 25 to the QuantUMS preprint repository https://t.co/jA2IQSiION. Inlcudes improved QuantUMS and some fixes. This version has quite a number of major improvements over 1.8.1, we will make an official github release once thoroughly tested

[Alexey Nesvizhskii @nesvilab]

MSBooster manuscript led by @yangkl96 is out! In tandem with Percolator, it improves identification rates in #FragPipe using deep learning-based predictions (from DIA-NN). We illustrate it using HLA peptidomics, direct DIA, single-cell, and timsTOF data. https://t.co/DRtG1ATXtL

[Georges BEDRAN @GeorgesBEDRAN3]

Excited to share our recent work on the glycosylated immunopeptidome: https://t.co/3vFkK23g4n
Huge thanks to all the talented team members!
@DanPolasky @AlfaroJav @nesvilab
#Cancer #Immunotherapy #CancerResearch

[Eric Ohuma @ohumaeric]

Glad to see our work getting attention in my home country! Let's save the world's preterms - born too soon! #BornTooSoon @joylawn
@MARCH_LSHTM https://t.co/4xucygkfpx

[Cancer Immunology Research @CIR_AACR]

The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides— by @Sachinskote, @AlfaroJav et al.
https://t.co/9egzKAQdYV
@GeorgesBEDRAN3 @im_into_science @znz8 @apalkowski @goodlettlab1

[CancerVaccines @ic2_vs]

Publication alert from ICCVS! 👏👏👏
Recent results available now in Cancer Immunology Research: https://t.co/dCPeLJsiOE @GeorgesBEDRAN3

[Georges BEDRAN @GeorgesBEDRAN3]

Exciting news! Our latest results are now available in Cancer Immunology Research: https://t.co/E2gtWrKSzA. We developed a proteogenomic strategy to discover non-canonical MHC-associated peptides from non-coding regions.

[Lauren Stopfer, PhD @lstops]

We’re HIRING! Come join me on my latest adventure at 🔬Aethon Therapeutics located in NYC!🗽

We’re looking for curious and motivated researchers to join us in creating novel Ab therapeutics at our early-stage #startup

Apply or DM for more info: https://t.co/rY0XQ4qRFP